131I-iodofalan (TLX101) / Telix, China Grand Pharma - LARVOL DELTA

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Jun 2027

Enrollment closed • Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

131I-TLX-101-003: A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma (clinicaltrialsregister.eu) - P2/3 | N=30 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

TLX101-Tx is currently also under evaluation in the pivotal IPAX BrIGHT trial to assess the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone in patients with recurrent glioblastoma (last line) (GlobeNewswire) - "IPAX BrIGHT is actively enrolling and dosing patients in Australia and the Netherlands and is also approved in Austria and Belgium with enrollment to begin soon."

Trial status • Glioblastoma

Telix Pharmaceuticals Limited…announces that the IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment (GlobeNewswire) - "No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum administered dose in the study....Twelve patients were enrolled into three dose escalating cohorts across four sites in Australia, Austria and the Netherlands to assess the safety and tolerability, and to assess the maximum tolerated dose (MTD) for further development."

Enrollment closed • Trial status • Glioblastoma

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma (GlobeNewswire) - "The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence."

Trial status • Glioblastoma

Therapeutics Business Unit:…TLX101-Tx (131I-iodofalan) (PRNewswire) - "Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma. The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium."

Trial status • Glioblastoma

131I-TLX-101-003: A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma (clinicaltrialsregister.eu) - P2/3 | N=30 | Not yet recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

New P2/3 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Therapeutics business (The Manila Times) - "Telix is enrolling patients at Australian sites in IPAX-BrIGHT, an international pivotal trial of TLX101-Tx in patients with recurrent glioblastoma. European sites are expected to join the study in Q1 2026."

Trial status • Glioblastoma

IPAX BrIGHT: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P3 | N=50 | Recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Telix Announces Record-Breaking Presence at EANM 2025 (PRNewswire) - "'Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC, the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC. Telix will host a sponsored symposium on CAIX and FAP targeting theranostics, and abstracts will also be presented from Telix's pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global access to innovative cancer imaging and therapy.'"

Clinical data • Preclinical • Trial status • Castration-Resistant Prostate Cancer • Glioblastoma • Ovarian Cancer • Renal Cell Carcinoma • Triple Negative Breast Cancer

A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma ( IPAX-3 ) - Part 1 (ANZCTR) - P3 | N=18 | Not yet recruiting | Sponsor: Telix Pharmaceuticals

New P3 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

IPAX BrIGHT: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - P3 | N=50 | Not yet recruiting | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

New P3 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

TLX101 Development Program and Registration-Enabling Study Update (GlobeNewswire) - "Telix has submitted for ethics approval a registration-enabling study of TLX101 in recurrent glioblastoma. Subject to approval this will enable patient enrolment to commence at Australian sites in H2 2025, ahead of international expansion. Following the successful pre-IND meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, the Company is also on track to submit an IND application in H1 2025, with the goal of commencing the study at U.S. sites in H2 2025."

IND • Trial status • Glioblastoma

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate (GlobeNewswire) - P2 | N=10 | IPAX-Linz-01 (2021-006426-43) | "Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis....Preliminary results from IPAX-Linz will be presented by Dr. Pichler at the Nuclear Medicine and Neurooncology (NMN) Symposium taking place in Vienna, Austria from 9 – 10 May 2025."

P2 data • Glioblastoma

18F-Floretyrosine Expanded Access Program (clinicaltrials.gov) - P=N/A | N=0 | Available | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

New trial • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

IPAX-2: Phase 1 safety and dose finding study of [131I]IPA plus standard of care in patients with newly diagnosed glioblastoma (SNO 2024) - P1 | "18F-FET PET will be used to identify suitable candidates with LAT1/2 overexpression, establish a baseline, and provide quantitative follow-up information. Primary outcome measures are 1) incidence rate treatment-emergent adverse events and 2) safety and tolerability by determining the dose-limiting toxicity, maximum tolerated dose, and recommended phase 2 dose."

Clinical • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara) Brain Cancer Imaging Agent (GlobeNewswire) - "Telix Pharmaceuticals Limited...announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA goal date of 26 April 2025, paving the way for a U.S. commercial launch in 2025...Pixclara to be potentially utilised as a companion diagnostic agent to TLX101 (131I-iodofalan, or 131I-IPA), Telix’s LAT1-targeting investigational glioblastoma (GBM) therapy..."

Diagnostic • FDA filing • PDUFA • Glioblastoma

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM) (PRNewswire) - "Telix's extensive theranostic pipeline will be showcased in presentations covering...TLX101 (131I-iodofalan or 131I-IPA) glioblastoma therapy; TLX66 (90Y-besilesomab) bone marrow conditioning therapy; TLX252 (225Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy..."

Clinical data • Glioma

Feasibility and tolerability of [¹³¹I]I-PA monotherapy in progressive and recurrent high grade gliomas; an ongoing single institution case series. (EANM 2024) - "Aim/Introduction: In a phase I-study, safety and tolerability of intravenous 4-L-[131I]iodo-phenylalanine ([¹³¹I]I-PA, TLX101, Telix Pharmaceuticals) administered concurrently with second line external beam radiation therapy in patients with recurrent glioblastoma has been demonstrated, with encouraging preliminary efficacy data... In this ongoing case series of [1³¹I]I-PA monotherapy in recurrent high-grade gliomas, treatment was feasible and well tolerated. Adequate targeting was revealed at post-therapy SPECT imaging."

Clinical • Monotherapy • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Impact of FET-PET imaging in surveillance of theranostic treatment with 4-L-[131I]iodo-phenylalanine ([131I]IPA) in relapsed glioblastoma patients (EANO 2024) - "This pilot study demonstrated different outcome in respect of PFS depending on whether MRI or PET RANO criteria have been used for analysis. Further, application of PET RANO criteria showed varying results in terms of response for each individual parameter (TBRmax, TBRmean and PETvolume). Based on our data, the value of an additional PET scan for a valid prediction of response in recurrent GBM patients must be discussed."

Clinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • PAX1

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances (PRNewswire) - P1/2 | N=10 | IPAX-1 (NCT03849105) | Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | "Telix Pharmaceuticals Limited...announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma....All dosing regimens were well tolerated....Stable disease with MRI assessment was observed in 4 of 9 patients at 3 months post-treatment (3-month follow-up, 1 patient did not reach protocol-mandated end of study), yielding a response rate of 44.4%....Median progression-free survival was 4.3 months (95% confidence interval, 3.3–4.5), while median OS was 13 months from the initiation of treatment (95% confidence interval, 7.1–27), or 23 months from initial diagnosis."

P1 data • Glioblastoma

Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([131I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1). (PubMed, Neurooncol Adv) - "Median progression-free survival was 4.3 months (95% confidence interval [CI]: 3.3-4.5), while median overall survival was 13 months (95% CI: 7.1-27). Single or fractionated doses of [131I]IPA plus XRT were associated with acceptable tolerability and specific tumor targeting in patients with recurrent GBM, warranting further investigation."

Journal • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

With IPO on ice, radiopharma Telix to raise nearly $400M in bond sale (Firstwordpharma Press Release) - "Telix Pharmaceuticals has turned to the bond market to raise funds to accelerate clinical development of its theranostic portfolio, just over a month after abandoning plans to list its shares in the US. The Australian company noted Tuesday that it expects to pull in AUD 600 million ($398 million) through an offering of convertible notes....The funds will go toward label-expansion studies to broaden the market opportunity across its portfolio of diagnostic imaging agents and to conduct pivotal trials of two therapy programmes. These include TLX250 (177Lu-DOTA-girentuximab) for renal cancer and TLX101 (131I-IPA) for glioblastoma."

Financing • Brain Cancer • CNS Tumor • Genito-urinary Cancer • Glioblastoma • Glioma • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma (PRNewswire) - "Telix Pharmaceuticals Limited...announces that a first patient has been dosed in a Phase I study of the Company's investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma....IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with external beam radiation therapy (EBRT) and temozolomide in front-line glioblastoma. Twelve patients are expected to be recruited to evaluate whether the observed safety and drug interaction profile remains suitable in this setting before progressing to a proof-of-concept Phase II study."

Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor